Pharmacokinetics of free and total mycophenolic acid in paediatric and adult renal transplant recipients: Exploratory analysis of the effects of clinical factors and gene variants

被引:5
作者
Liu, Yan [1 ,2 ,3 ]
Zhang, Huanxi [4 ]
Li, Jun [4 ]
Liu, Longshan [4 ]
Wu, Chenglin [4 ]
Fu, Qian [4 ]
Huang, Min [3 ]
Chen, Xiao [1 ]
Wang, Changxi [4 ]
Chen, Pan [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pharm, 58 Zhong Shan Er Lu, Guangzhou, Peoples R China
[2] First Hosp Nanchang, Dept Pharm, Nanchang, Jiangxi, Peoples R China
[3] Sun Yat Sen Univ, Sch Pharmaceut Sci, Inst Clin Pharmacol, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, 58 Zhong Shan Er Lu, Guangzhou, Peoples R China
关键词
free fraction; mycophenolic acid; pharmacogenomics; pharmacokinetics; renal transplantation; AFRICAN-AMERICAN; MOFETIL; POLYMORPHISMS; EXPRESSION; EXPOSURE; AGE; VARIABILITY; THERAPY; PHARMACODYNAMICS; ASSOCIATION;
D O I
10.1111/bcpt.13743
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Clinical and genetic influencing factors on free fraction of mycophenolic acid (MPA) have rarely been discussed. The present study investigated whether the clinical and genetic factors could explain the variability in the pharmacokinetics of free MPA (fMPA) and total MPA (tMPA) in Chinese paediatric and adult renal transplant recipients. Twenty-eight paediatric and 31 adult patients were enrolled, and the concentrations of tMPA and fMPA were determined at 0 h (predose) and 0.5, 1, 1.5, 2, 4, 5, 8, 9, 10 and 12 h after mycophenolate mofetil administration. Genetic polymorphisms of UGTs (rs671448, rs1042597, rs2741049, rs62298861, rs7439366, rs12233719) and ABCC2 (rs717620) were simultaneously determined. The clinical and genetic data were analysed and reported. tMPA and fMPA concentrations adjusted for dose per body weight were consistently higher in adults than in paediatric patients. In the paediatric group, only albumin and time after transplantation correlated significantly with the MPA-free fraction variation, which could explain 32.4% of the variability. Besides, ABCC2 polymorphism, albumin and time after transplantation correlated significantly with the MPA-free fraction variation in adults, which could explain 56.9% of the variability. The influencing factors in the paediatric group are different from those in adults, which may be due to age-related transporter expression.
引用
收藏
页码:60 / 73
页数:14
相关论文
共 56 条
[1]   Mycophenolate mofetil and its mechanisms of action [J].
Allison, AC ;
Eugui, EM .
IMMUNOPHARMACOLOGY, 2000, 47 (2-3) :85-118
[2]   Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant [J].
Atcheson, BA ;
Taylor, PJ ;
Mudge, DW ;
Johnson, DW ;
Hawley, CM ;
Campbell, SB ;
Isbel, NM ;
Pillans, PI ;
Tett, SE .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (03) :271-280
[3]   Changes in plasma protein binding have little clinical relevance [J].
Benet, LZ ;
Hoener, BA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (03) :115-121
[4]   Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology [J].
Bergan, Stein ;
Brunet, Merce ;
Hesselink, Dennis A. ;
Johnson-Davis, Kamisha L. ;
Kunicki, Pawel K. ;
Lemaitre, Florian ;
Marquet, Pierre ;
Molinaro, Mariadelfina ;
Noceti, Ofelia ;
Pattanaik, Smita ;
Pawinski, Tomasz ;
Seger, Christoph ;
Shipkova, Maria ;
Swen, Jesse J. ;
van Gelder, Teun ;
Venkataramanan, Raman ;
Wieland, Eberhard ;
Woillard, Jean-Baptiste ;
Zwart, Tom C. ;
Barten, Markus J. ;
Budde, Klemens ;
Dieterlen, Maja-Theresa ;
Elens, Laure ;
Haufroid, Vincent ;
Masuda, Satohiro ;
Millan, Olga ;
Mizuno, Tomoyuki ;
Moes, Dirk J. A. R. ;
Oellerich, Michael ;
Picard, Nicolas ;
Salzmann, Linda ;
Toenshoff, Burkhard ;
van Schaik, Ron H. N. ;
Vethe, Nils Tore ;
Vinks, Alexander A. ;
Wallemacq, Pierre ;
Asberg, Anders ;
Langman, Loralie J. .
THERAPEUTIC DRUG MONITORING, 2021, 43 (02) :150-200
[5]   The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants [J].
Bernard, O ;
Guillemette, C .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (08) :775-778
[6]   Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation [J].
Cattaneo, D ;
Perico, N ;
Gaspari, F ;
Gotti, E ;
Remuzzi, G .
KIDNEY INTERNATIONAL, 2002, 62 (03) :1060-1067
[7]   Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients [J].
Cattaneo, D ;
Gaspari, F ;
Ferrari, S ;
Stucchi, N ;
Del Priore, L ;
Perico, N ;
Gotti, E ;
Remuzzi, G .
CLINICAL TRANSPLANTATION, 2001, 15 (06) :402-409
[8]   Pharmacokineitic study of mycophenolic acid in Korean kidney transplant patients [J].
Cho, EK ;
Han, DJ ;
Kim, SCE ;
Burckart, GJ ;
Venkataramanan, R ;
Oh, JM .
JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (07) :743-750
[9]   Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children [J].
de Wildt, Saskia N. .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (08) :935-948
[10]   Paediatric use of mycophenolate mofetil [J].
Downing, Heather J. ;
Pirmohamed, Munir ;
Beresford, Michael W. ;
Smyth, Rosalind L. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (01) :45-59